Comparative Pharmacology
Head-to-head clinical analysis: HYDROCORTISONE VALERATE versus MAGNACORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROCORTISONE VALERATE versus MAGNACORT.
HYDROCORTISONE VALERATE vs MAGNACORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to induce anti-inflammatory, antipruritic, and vasoconstrictive effects.
Corticosteroid receptor agonist; modulates gene transcription to produce anti-inflammatory and immunosuppressive effects.
Apply a thin film to affected area twice daily. Topical use only.
5 mg orally once daily for 7 days, then 5 mg orally every other day for 7 days. Alternatively, 1 mg/kg intravenously every 12 hours for 14 days.
None Documented
None Documented
Terminal elimination half-life is approximately 2-3 hours for the parent drug; 18-36 hours for the active metabolites (clinical context: duration of action is prolonged due to local tissue retention and metabolite activity)
3.5 ± 0.8 hours (terminal); prolonged in renal impairment (up to 12 hours in ESRD) and hepatic disease; requires dose adjustment in CrCl <30 mL/min
Renal (approximately 80% as metabolites, <1% unchanged), fecal/biliary (approximately 20% as metabolites)
Renal (80% as unchanged drug and metabolites, primarily via glomerular filtration and tubular secretion); biliary/fecal (15%)
Category D/X
Category C
Corticosteroid
Corticosteroid